Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Tetsuo Takehara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5036-3457; OpenAlex author ID A5040891927. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
24
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers

Papers 10

  1. The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary mucinous neoplasia. Last author DOI 10.1016/j.pan.2023.11.005↗
  2. The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis. Last author DOI 10.1038/s41598-024-62498-x↗
  3. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity. Last author DOI 10.1186/s13046-023-02831-w↗
  4. Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss. Last author DOI 10.1111/cas.15569↗
  5. Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions. Last author DOI 10.1097/mpa.0000000000001521↗
  6. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels. Last author DOI 10.1371/journal.pone.0235573↗
  7. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. Last author DOI 10.1016/j.bbrc.2019.07.020↗
  8. CKAP4, a DKK1 Receptor, Is a Biomarker in Exosomes Derived from Pancreatic Cancer and a Molecular Target for Therapy. Co-author DOI 10.1158/1078-0432.ccr-18-2124↗
  9. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function. Co-author DOI 10.1093/jjco/hyu224↗
  10. Adiponectin inhibits murine pancreatic cancer growth. Last author DOI 10.1007/s10620-014-3175-6↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teppei Yoshioka · 7 shared papers, 2019–2024 · strength 0.87
  2. Katsuhiko Sato · 6 shared papers, 2020–2024 · strength 0.78
  3. Kenji Ikezawa · 3 shared papers, 2019–2024 · strength 0.35
  4. Junya Okabe · 2 shared papers, 2023–2024 · strength 0.30
  5. Hidetoshi Eguchi · 3 shared papers, 2015–2023 · strength 0.27
  6. Tadashi Kegasawa · 2 shared papers, 2019–2024 · strength 0.25
  7. Takuo Yamai · 2 shared papers, 2020 · strength 0.20
  8. Kengo Matsumoto · 1 shared paper, 2024 · strength 0.16
  9. Motohiro Hirao · 1 shared paper, 2024 · strength 0.16
  10. Masaya Higashiguchi · 1 shared paper, 2023 · strength 0.14
  11. Kazuma Daiku · 1 shared paper, 2023 · strength 0.14
  12. Makiko Urabe · 1 shared paper, 2020 · strength 0.10
  13. Tsunekazu Mizushima · 1 shared paper, 2019 · strength 0.08
  14. Soichiro Mori · 1 shared paper, 2019 · strength 0.08
  15. Hirokazu Kimura · 1 shared paper, 2019 · strength 0.08
  16. Ryota Sada · 1 shared paper, 2019 · strength 0.08
  17. Akira Kikuchi · 1 shared paper, 2019 · strength 0.08
  18. Motohiko Kato · 1 shared paper, 2014 · strength 0.05
  19. Tadafumi Asaoka · 1 shared paper, 2015 · strength 0.05
  20. Yuichiro Doki · 1 shared paper, 2015 · strength 0.05
  21. Kazuhiko Ogawa · 1 shared paper, 2015 · strength 0.05
  22. Yoshito Tomimaru · 1 shared paper, 2015 · strength 0.05
  23. Shigeru Marubashi · 1 shared paper, 2015 · strength 0.05
  24. Hiroaki Nagano · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.